Fortitude Biomedicines

Fortitude Biomedicines, our people are our greatest assets driving toward a common goal of creating precision antibody-based therapies for autoimmune diseases and cancer.  Taking time to step away from the lab and office to connect as a team reminds us that the strongest ideas are built on trust, collaboration, and shared purpose. Every conversation, every laugh, and every new connection strengthen the culture that drives our work forward. We're united by a common mission: to develop transformative therapies for people living with complex diseases such as axial spondyloarthritis (axSpA) and treatment-resistant cancers. That mission inspires everything we do, and it's made possible by an exceptional team committed to making a meaningful difference for patients. Grateful for a day spent together and even more excited about what we'll accomplish together. #Biotech #Culture #Innovation #axSpA #Teamwork #PatientFirst To learn more about Fortitude Biomedicines lead program in development for treatment of axSpA, visithttps://lnkd.in/eh5bg797 Fortitude Biomedicines #axSpA  #bispecificantibodies #ADCs #DACs 

Fortitude Biomedicines is pleased to showcase Dr. Rahul Patel, MD, FACP, FACR review publication in the May edition of Best Practice & Research Clinical Rheumatology, “Axial spondyloarthritis: Moving beyond cytokine based therapies to cellular targets and advanced therapeutics”.  There remains substantial unmet medical need for patients living with Axial Spondyloarthritis (#axSpA), underscoring the importance of advancing innovative therapeutic approaches. To read this article, visit https://lnkd.in/e7qgmmNQ To learn more about Fortitude Biomedicines lead program in development for treatment of axSpA, visit https://lnkd.in/eh5bg797 #axSpA #bispecificantibodies #ADCs #DACs Spondylitis Association of America Axial Spondyloarthritis International Federation

Fortitude Biomedicines is pleased to showcase Dr. Rahul Patel, MD, FACP, FACR review publication in the May edition of Best Practice & Research Clinical Rheumatology, “Axial spondyloarthritis: Moving beyond cytokine based therapies to cellular targets and advanced therapeutics”.  There remains substantial unmet medical need for patients living with Axial Spondyloarthritis (#axSpA), underscoring the importance of advancing innovative therapeutic approaches. To read this article, visit https://lnkd.in/e7qgmmNQ To learn more about Fortitude Biomedicines lead program in development for treatment of axSpA, visit https://lnkd.in/eh5bg797 #axSpA #bispecificantibodies #ADCs #DACs Spondylitis Association of America Axial Spondyloarthritis International Federation

Fortitude Biomedicines is pleased to be included in the April edition of the journal of #NatureCancer, “New Payloads Drive Next-Generation-Drug Conjugates”. At Fortitude, we are driving innovating therapies using molecular glue as payloads for next generation ADCs. https://lnkd.in/dq4CVzA3 To learn more about our GLUE-DAC platform and programs, visit https://fortitudebio.com/ #AxSpA #TCellDepletion #bispecificantibodies #ADCs #DACs

Fortitude Biomedicines is pleased to be included in the April edition of the journal of #NatureCancer, “New Payloads Drive Next-Generation-Drug Conjugates”. At Fortitude, we are driving innovating therapies using molecular glue as payloads for next generation ADCs. https://lnkd.in/dq4CVzA3 To learn more about our GLUE-DAC platform and programs, visit https://fortitudebio.com/ #AxSpA #TCellDepletion #bispecificantibodies #ADCs #DACs

Fortitude Biomedicines is pleased to showcase Kathy Derakhchan, PhD, DSP publication, “25 years of applying the 3Rs principles in safety pharmacology: success stories and future perspectives” Frontiers in Physiology, April 26, 2026. This publication highlights decades of progress in integrating new approach methodologies (NAMs) and Replacement, Reduction, and Refinement (3Rs) of animal use into safety pharmacology. https://lnkd.in/evvQFh8K Kathy Derakhchan, PhD, DSP is the chair of the Safety Pharmacology Society 3Rs working group and co-leader of the project. We’re fortunate to have Kathy as part of our team. Her expertise and commitment to advance safety pharmacology  continues to make a meaningful impact both within our organization and across the industry. Fortitude Biomedicines Safety Pharmacology Society #AxSpA #TCellDepletion #bispecificantibodies #ADCs #DACs

Today we are joining the Spondylitis Association of America to raise awareness for Axial Spondyloarthritis (#AxSpA). Join the cause and take a walk. Be part of the Walk your A.S. Off Day. AxSpA is a chronic, debilitating rheumatic inflammatory disease affecting the axial skeleton. It impacts more than 1.8M people in the US and more than 50M patients worldwide. Patients have persistent inflammatory back pain, stiffness, and enthesitis (inflammation of tendons and ligaments attached to the bone). Without timely and effective treatment, AxSpA can lead to progressive structural damage and long-term functional impairment. Fortitude Biomedicines team has laced up to join the cause. Our lead program in development has the potential to offer hope for patients with Axial Spondyloarthritis (#AxSpA). #ADCs #DACs Fortitude Biomedicines Spondylitis Association of America #AxSpA #WYASO

Saturday, May 2 is #WorldASDay2026. Fortitude Biomedicines is pleased to join the cause with Axial Spondyloarthritis International Federation to raise awareness for Axial Spondyloarthritis (#AxSpA). This year’s theme is #NotOnlyBackPain. #AxSpA affects much more than the spine. Alongside pain and stiffness, patients also suffer from fatigue, mobility issues and ocular uveitis, #IBS, or psoriasis. #ADCs #DACs Fortitude Biomedicines Axial Spondyloarthritis International Federation #AxSpA #WorldASDay2026

Fortitude Biomedicines is pleased to announce a poster presentation at the #AACR conference in San Diego on Monday April 20, 2026. To learn more about FortitudeBio's novel #Glue-DAC ADC program, visit Dr. Jan Theunissen’s poster, titled “A novel  BRD4 degrader–HER2-targeting antibody–drug conjugate (DAC) overcomes Trastuzumab Deruxtecan resistance in HER2-positive cancers”(Post Number 2406). We are excited to share the results of our collaboration with Dr. Jin Wang, Endowed Professor in Pharmacology at Baylor College of Medicine. At Fortitude Biomedicines, we are harnessing the power of our proprietary Glue-DAC ADC platform and are redefining what’s possible in drug discovery. #ADCs #DACs #AACR #ResistanceInOncology @FortitudeBio @AACR @degrader-ADCs

Fortitude Biomedicines is pleased to announce lead program targeting disease-driven T-cell signaling pathways for the treatment of Axial Spondyloarthritis The appointment of Dr. Rahul Patel as Senior Vice President of Clinical Development strengthens leadership team and provides critical support to accelerate clinical development of lead program To learn more https://lnkd.in/e9mw8dZz #BispecificAntibody, #AxSpA